PMID- 33511553
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210518
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 3
DP  - 2021 Mar
TI  - The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of 
      T2DM: A Collaborative Delphi Survey-Based Consensus from India.
PG  - 679-695
LID - 10.1007/s13300-021-01002-4 [doi]
AB  - INTRODUCTION: This Delphi study aims to provide evidence-based expert opinion on 
      the usage and current position of gliclazide in type 2 diabetes mellitus (T2DM) 
      management in India. METHODS: The single interaction modified Delphi-based 
      methodology was used to collect opinions on gliclazide usage and its position in 
      diabetes management from 338 endocrinologists/diabetologists who have had 
      clinical experience with gliclazide. Participants, using a 9-point scale, were 
      asked to rate eight statements comprising a total of 52 items on the related 
      topics. RESULTS: The Delphi consensus suggests that in drug-naive patients with 
      T2DM, intolerant to metformin or in whom metformin is contraindicated, dual 
      therapy of gliclazide/gliclazide-modified release (MR) should be considered along 
      with a dipeptidyl peptidase 4 (DPP4) inhibitor if glycated hemoglobin A1c level 
      is greater than 7.5% and with insulin if the A1c level is greater than 9%. If the 
      patients are inadequately controlled with metformin (A1c greater than 6.5% after 
      3 months of therapy), gliclazide/gliclazide-MR shall be added on to the treatment 
      regimen to achieve greater and sustained reductions in A1c levels. However, it 
      was not preferred over other antidiabetic classes in such clinical settings 
      except alpha-glucosidase inhibitors (AGI). Early addition of 
      gliclazide/gliclazide-MR shall be preferred over the up-titration of metformin 
      beyond half-maximal dose for effective management of T2DM. 
      Gliclazide/gliclazide-MR can be used safely in patients with diabetes and 
      cardiovascular and chronic kidney disease. It can be used in older patients with 
      T2DM as it does not have active metabolites and has a low risk of hypoglycemia. 
      CONCLUSION: The expert panel proposed consideration of monotherapy or dual 
      therapy of gliclazide as an ideal choice in patients with T2DM because of its 
      efficacy, long-term glycemic control, favorable renal outcomes, cardiovascular 
      safety, and an optimal safety profile.
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
FAU - Unnikrishnan, A G
AU  - Unnikrishnan AG
AD  - Department of Endocrinology and Diabetes, Chellaram Diabetes Institute, Pune, 
      Maharashtra, India.
FAU - Bantwal, Ganapathi
AU  - Bantwal G
AD  - Department of Endocrinology, St John's Medical College, Bangalore, Karnataka, 
      India.
FAU - Das, Sambit
AU  - Das S
AD  - Department of Endocrinology, Apollo Hospitals, Bhubaneswar, India.
FAU - Polavarapu, Nareen Krishna
AU  - Polavarapu NK
AD  - Medical Affairs, Dr. Reddy's Laboratories Limited, Hyderabad, India. 
      nareenkrishna.p@drreddys.com.
FAU - Gaurav, Kumar
AU  - Gaurav K
AD  - Medical Affairs, Dr. Reddy's Laboratories Limited, Hyderabad, India.
LA  - eng
PT  - Journal Article
DEP - 20210128
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7947040
OTO - NOTNLM
OT  - Delphi questionnaire
OT  - Endocrinology
OT  - Gliclazide
OT  - Gliclazide-MR
OT  - Single interaction modified Delphi process
OT  - Type 2 diabetes
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
PMCR- 2021/01/28
CRDT- 2021/01/29 06:01
PHST- 2020/11/03 00:00 [received]
PHST- 2021/01/12 00:00 [accepted]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
PHST- 2021/01/29 06:01 [entrez]
PHST- 2021/01/28 00:00 [pmc-release]
AID - 10.1007/s13300-021-01002-4 [pii]
AID - 1002 [pii]
AID - 10.1007/s13300-021-01002-4 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Mar;12(3):679-695. doi: 10.1007/s13300-021-01002-4. Epub 2021 
      Jan 28.